FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

A patient’s response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait, and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved predictive biomarkers (progra1mmed cell death ligand-1 (PD-L1); microsatellite instability (MSI); tumor mutational bur...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark, Zhou, Xin, Zhao, Gexin, Chen, Hong, Li, Xinmin
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8216110/
https://ncbi.nlm.nih.gov/pubmed/34164344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.683419
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados